Program
Picibanil
Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Neoplasms · Lymphatic Abnormalities, led by Protara Therapeutics.
Furthest: phase 3, since Mar 13, 20265 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Protara Therapeutics | 53 open or running | phase 3since Mar 13, 2026 | Oct 7, 2021 | Dec 2026phase 2 · NCT05871970 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 7, 2021First studies: 2 phase 1 studies in Non-Muscle Invasive Bladder NeoplasmsFirst studyNCT05085990, NCT05085977
- May 11, 2023Phase 2 study in Lymphatic AbnormalitiesNCT05871970 · 38 planned · United States
- Jun 29, 2023Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT05951179 · 131 planned · United States, Argentina, Brazil and more
- Mar 13, 2026Phase 3 study in NeoplasmsPhase 3 reachedNCT07480356 · 284 planned · United States, Ukraine
Ahead
- Dec 2026Primary completion: phase 2 study in Lymphatic AbnormalitiesNCT05871970
- Apr 2028Primary completion: phase 3 study in NeoplasmsNCT07480356
- Oct 2031Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT05951179
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07480356Neoplasms · United States, Ukraine | 3 | Recruiting | Apr 2028 | 284 |
| NCT05951179Non-Muscle Invasive Bladder Neoplasms · United States, Argentina, Brazil and more | 2 | Recruiting | Oct 2031 | 131 |
| NCT05871970Lymphatic Abnormalities · United States | 2 | Recruiting | Dec 2026 | 38 |
| NCT05085990Non-Muscle Invasive Bladder Neoplasms · United States | 1 | Completed | Sep 12, 2024 | 10 |
| NCT05085977Non-Muscle Invasive Bladder Neoplasms · United States, Moldova, Republic of, Romania and more | 1 | Completed | Sep 3, 2024 | 12 |
How it is read
Names in the registry
- “TARA-002”, 5 entries
Conditions, from the studies’ own filings
- Non-Muscle Invasive Bladder Neoplasms, 3 studies
- Neoplasms, 1 study
- Lymphatic Abnormalities, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.